Did you know?
ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.
Free Newsletter
Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!
Free Report
Fosun-Partnered COVID-19 Vaccine Approved in UK
Fosun's
In March, Fosun partnered the mRNA vaccine with BioNTech in a deal worth up to $135 million, which included a $50 million Fosun investment in BioNTech.
The China Phase II trial will specifically examine seroconversion rates and the geometric mean titer of SARS-CoV-2 serum neutralizing titers. It will also report on the safety and tolerability of the vaccine seven and 14 days after each vaccination.
“The Phase II clinical study with BNT162b2 in China will not only provide key data for the launch of the vaccine in China, but also may play a positive role in the widespread promotion and use of the vaccine throughout Asia and around the world,” Aimin Hui, MD, PhD, chief medical officer at Fosun, said in a statement.
The
See our other articles on Fosun Pharma and BioNTech.
Disclosure: none.
ChinaBio® News
Greg Scott Interviewed at BIO-Europe Spring
How to bring your China assets to China in 8 minutes
"Mr. Bio in China."
Mendelspod Interview
Multinational pharma held to a higher standard in China